ANUHPHR · Anuh Pharma Ltd · Biotechnology & Drugs
ANUHPHR · Anuh Pharma Ltd · Biotechnology & Drugs
As of 06 Nov close
52-week range
18.0% below 52-week high
52-week range: as of 06 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 53 days old
Revenue (latest Q)
₹194 Cr
Revenue YoY
PAT YoY
+37.6%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
2.6
P/S (TTM)
1.2
Sector P/E
36.3
Dividend yield
+1.6%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| ANUHPHR (this stock) | 18.4 | 2.6 | +5.7% | +12.5% | 0 | +1.6% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
stable
MF
Not available from data source
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
No related news.
Concalls & investor presentations
AI-generatedKey takeaway: The investor presentation for Q1 FY 2026-27 reported that Anuh Pharma Limited achieved an operating revenue of Rs. 193.81 crores, reflecting a 3.93% year-over-year increase. EBITDA rose by 41.56% to Rs. 19.36 crores, with a margin improvement to 9.99%. Profit After Tax (PAT) was reported at Rs. 11.42 crores, up 37.63% year-over-year, resulting in an EPS of Rs. 1.14. The company highlighted a production increase of 19.46% to 491 MT. Management attributed the profit growth to a richer product mix, disciplined cost control, and enhanced throughput from existing assets. The presentation also outlined future growth strategies, including volume expansions and market diversification, with a goal of achieving a steady growth rate of 15-20% per annum. Anuh Pharma emphasized its commitment to sustainable growth and corporate social responsibility initiatives.
Management emphasized strong financial performance and growth strategies.
Sourced from an exchange-filed presentation, dated 19 Aug 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: The investor presentation for Anuh Pharma Limited for Q4 FY 2025-26 highlighted significant achievements, including successful USFDA and EU GMP inspections. Management reported a revenue increase of 15.66% year-over-year, reaching Rs. 776 crore, driven by strong volume growth and strategic market expansion. EBITDA for the year was Rs. 67.84 crore, reflecting a 6.52% increase. The company emphasized its commitment to quality and regulatory compliance, which has reinforced its reputation as a global API partner. The presentation outlined a strategic focus on process innovation, cost optimization, and market diversification to support sustainable growth. Management expressed gratitude to employees and stakeholders for their support and highlighted ongoing corporate social responsibility initiatives. The document also provided insights into the company's infrastructure and future product developments, including new therapeutic applications under development.
Management emphasized strong performance and strategic growth initiatives.
Sourced from an exchange-filed presentation, dated 28 May 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: The investor presentation for Anuh Pharma Limited for Q3 FY 2025-26 highlighted the company's strong operational performance, with revenue reaching ₹201 Cr, an increase from ₹186 Cr in the previous quarter. The operating margin improved to 23.28%, up from 22.24%, and EBITDA rose significantly to ₹20.91 Cr, reflecting a margin of 10.60%. Year-to-date revenue also increased to ₹578.02 Cr compared to ₹471.43 Cr in the same period last year. Management reported successful completion of a USFDA inspection with zero observations, emphasizing their commitment to quality. The presentation outlined a focus on capacity expansion, operational efficiencies, and strategic growth opportunities, including new product development in the anti-diabetic and anti-TB segments. The company also reported a strong commitment to corporate social responsibility initiatives.
Management emphasized strong performance and strategic growth initiatives.
Sourced from an exchange-filed presentation, dated 13 Feb 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedAnuh Pharma Limited reported a 16% increase in total revenue to Rs. 776 Cr in FY2025-26 compared to Rs. 671 Cr in the previous year, driven by growth in anti-malarial, antibiotic, and expectorant segments. However, profit before tax decreased by 11% to Rs. 54 Cr, and profit after tax fell by 13% to Rs. 41 Cr. The company recommended a final dividend of Rs. 1.50 per equity share. No significant regulatory orders, insolvency proceedings, or fraud reports were noted. The company has no outstanding statutory dues beyond six months and has not defaulted on loans or borrowings.
- Revenue increased by 16% to Rs. 776 Cr in FY2025-26.
- Profit before tax decreased by 11% to Rs. 54 Cr, and profit after tax fell by 13% to Rs. 41 Cr.
- No significant regulatory orders, insolvency proceedings, or fraud reports were noted.
- No statutory dues outstanding beyond six months.
- No defaults on loans or borrowings reported.
Key takeaway: Anuh Pharma Limited achieved revenue growth in FY2025-26 but faced declining profitability, with no major regulatory or liquidity issues reported.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
No item of a kind that needs attention was stored for this company.
Contingent Liability
2 occurrencesRecent (last 12 months)
The company is involved in various legal proceedings and other regulatory matters relating to conduct of its business, with uncertain outcomes that could significantly impact its reported results and balance sheet position.
Earlier (1-3 years ago)
The company has contingent liabilities related to sales tax, GST, and income tax with amounts of Rs. 27.03 lakhs, Rs. 107.10 lakhs, and Rs. 34.56 lakhs respectively. These liabilities are based on orders from tax authorities and ongoing appeals.
Statutory dues in dispute
1 occurrenceEarlier (1-3 years ago)
The company has outstanding income tax and sales tax dues from 2017-18 to 2018-19, with disputes pending before the Commissioner of Income-Tax and Bombay High Court.